

of UTI are caused by multidrug-resistant organisms, and that only combinations of broad-spectrum antibiotics offer adequate coverage for nosocomial infections.

Conclusions: For the first time in Latin America, we provide high-quality data to guide empirical antibiotic recommendations for UTI in patients with cirrhosis.

Table: Proportion (95% CI) of UTI Episodes with Susceptibility to Different Antibiotic Regimens by Site of Infection Acquisition (n=278). Adequate options for stable patients are highlighted in light gray, and those for critically ill patients are highlighted in dark gray

Antibiotic Regimen	Community-acquired n= 119	Healthcare-associated n= 69	Nosocomial n= 90
Nitrofurantoin*	82 (73-89)	66 (51-78)	55 (43-67)
Quinolones	36 (28-46)	26 (17-38)	23 (16-33)
TMP-SMX (Trimethoprim-Sulfamethoxazole)	43 (34-52)	36 (25-48)	26 (18-36)
Ceftriaxone	51 (42-60)	29 (20-41)	21 (14-31)
Cefepime	53 (44-62)	31 (21-43)	27 (18-37)
Ceftazidime	47 (38-56)	29 (20-42)	22 (15-32)
Aminoglycoside	82 (74-88)	70 (58-80)	63 (52-73)
Piperacillin-tazobactam	61 (51-69)	46 (34-58)	29 (21-40)
Ertapenem	79 (71-86)	60 (48-71)	46 (37-57)
Colistin	80 (71-87)	63 (50-75)	69 (57-79)
Piperacillin-tazobactam + Vancomycin	61 (52-70)	52 (39-63)	32 (23-43)
Meropenem or Imipenem	90 (83-94)	77 (65-85)	56 (45-66)
Carbapenem + Vancomycin	91 (84-95)	82 (71-90)	58 (47-68)
Carbapenem + Linezolid	92 (85-96)	90 (80-95)	64 (54-74)
Aminoglycoside + Colistin	85 (77-90)	71 (59-81)	80 (69-87)
Ceftazidime-avibactam	83 (75-89)	68 (55-78)	68 (58-77)
Ceftazidime-avibactam + Aztreonam	68 (59-76)	54 (42-66)	72 (61-80)
Ceftolozane-tazobactam	85 (78-91)	70 (57-80)	73 (62-81)
Ceftazidime-avibactam + Vancomycin	95 (89-98)	88 (78-94)	76 (66-84)

The data from the 278 episodes with complete information are presented. For episodes with two isolations, susceptibility was assessed considering the coverage of both. * Nitrofurantoin was tested in 91 Community-acquired, 47 Health-associated and 65 nosocomial infections. Nitrofurantoin achieves good concentrations in urine but does not concentrate well in plasma and kidney parenchyma.

<https://doi.org/10.1016/j.aohep.2024.101671>

P-58 PILOT STUDY OF HEPATITIS E VIRUS SEROPREVALENCE IN HEPATITIS B AND DELTA CARRIERS IN THE WESTERN AMAZON

Caio Lopes Borges Andrade¹,
Luiz Felipe Monteiro Darzé¹,
Maurício de Souza Campos²,
Sidelcina Rugieri Pacheco³, Ezequiel Ridruejo⁴,
Juan Miguel Villalobos Salcedo⁵,
Katia Ingred da Silva Maia⁵, Tarcio Peixoto Roca⁵,
Deusilene Souza Vieira Dallacqua⁵,
Jucara Magalhaes Simoes¹, Robert Eduard Schaer¹,
Roberto Jose Meyer Nascimento¹,
Raymundo Paraná Ferreira Filho¹,
Songeli Menezes Freire¹, Maria Izabel Schinoni⁶

¹ Laboratório de Imunologia e Biologia Molecular, Universidade Federal da Bahia, Salvador, Brasil, Salvador, Brasil

² IDOMED - Instituto de educação médica - Faculdade Estácio, Alagoinhas, Brasil, Alagoinhas, Brasil

³ Hospital Universitário Professor Edgard Santos, Salvador, Brasil, Salvador, Brasil

⁴ Sección Hepatología, Departamento de Medicina. Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno "CEMIC". Ciudad Autónoma de Buenos Aires, Argentina., Buenos Aires, Argentina

⁵ Centro de Medicina Tropical de Rondônia - CEMETRON, Porto Velho, Brasil, Porto Velho, Brasil

⁶ Laboratório de Imunologia e Biologia Molecular, Universidade Federal da Bahia, Salvador, Brasil; Hospital Universitário Professor Edgard Santos, Salvador, Brasil., Salvador, Brasil

Conflict of interest: No

Introduction and Objectives: Hepatitis E virus (HEV) is a zoonotic virus transmitted via the fecal-oral route with a generally favorable prognosis. However, higher risks exist for pregnant or immunocompromised patients. Infection occurs through contaminated food, water, or direct contact with infected blood. Its asymptomatic nature and favorable prognosis likely contribute to underreporting in Brazil, especially in peri-urban and rural areas with limited healthcare access. **Objective:** To evaluate the seroprevalence of HEV in patients with mono-infection of Hepatitis B and co-infection with Delta virus in Rondônia.

Patients / Materials and Methods: An exploratory cross-sectional study using the Dia.Pro HEV Ab total ELISA kit for serological evaluation of 177 samples from the serum bank of the Molecular Virology Laboratory at Fiocruz-RO of patients with viral hepatitis from the Tropical Medicine Center (CEMETRON) in Rondônia. The samples were stratified into 74 VHD co-infected and 103 HBV mono-infected groups. The diagnosis of the Delta virus was performed using molecular biology on samples collected between 2018 and 2022. The results were analyzed using T-test and chi-square test.

Results and Discussion: The total sample consisted of 177 participants, including 95 men, 54 women, and 28 without information. The average age of participants was 41 years (M=41), with the Delta group averaging 40 years and the HBV mono-infected group averaging 42 years. Of the 74 VHB-VHD sera, 9 (12.16%) were HEV IgG positive, 58 (78.40%) were non-reactive, and 7 (9.45%) were indeterminate. Among the 103 HBV sera, 9 (8.73%) were HEV IgG positive, 86 (83.50%) were non-reactive, and 8 (7.76%) were indeterminate.

Conclusions: The findings of HEV in HBV and VHD patients in Rondônia showed results similar to those found in studies with other populations. This is the first study on HEV in HBV and VHD patients.

<https://doi.org/10.1016/j.aohep.2024.101672>

P-59 SOCIAL DETERMINANTS OF HEALTH AND INEQUITIES IN CHRONIC DISEASES: THE CASE OF LIVER DISEASES

Luisa Fernanda Santos Cuervo¹,
Adriana Varon Puerta²

¹ UNIVERSIDAD NACIONAL, Bogota, Colombia

² La Cardio, Bogota, Colombia

Conflict of interest: No

Introduction and Objectives: Cirrhosis is the leading cause of liver-related deaths worldwide. However, it should be highlighted that not only biology determines the disease, since ancient times it has been described that health is socially determined, however, today the same underlying problems continue to arise since its causes remain unresolved. It is clear that the mechanisms of society have a direct influence on the disease and only by taking these aspects into account can we understand social inequities in the field of health and intervene to correct them.

Patients / Materials and Methods: Retrospective descriptive ecological study using data from secondary sources, coming from mortality databases, morbidity databases of the National Public Health Surveillance System, Transplant Network, National Institute of Health and Liver and Transplant Associations.

Results and Discussion: Although vaccination, screening, and antiviral treatment campaigns for hepatitis B and C have reduced the disease burden in some parts of the world, concomitant increases in injection drug use, alcohol abuse, and metabolic syndrome threaten these trends, moreover, we can estimate that the affected population is much larger.